Twist Bioscience Corp
TWST
Market Cap$2.52B
Close$
$42.26
12.6% downside
Current Fair Value
12.6% downsideOvervalued by 12.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.52 Billion |
|---|---|
| Enterprise Value | $2.22 Billion |
| Dividend Yield | $0.0 (0.0%) |
| Earnings per Share | $-3.35 |
| Beta | 3.37 |
| Outstanding Shares | 58,225,999 |
| Avg 30 Day Volume | 1,249,156 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -13.09 |
|---|---|
| PEG | 56.68 |
| Price to Sales | 12.09 |
| Price to Book Ratio | 5.37 |
| Enterprise Value to Revenue | 8.01 |
| Enterprise Value to EBIT | -11.62 |
| Enterprise Value to Net Income | -12 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
ESG Score
No data
About Twist Bioscience Corp
CEO: Emily Leproust Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary techno...